Hyperfractionated Accelerated Radiotherapy (HART) for Anaplastic Thyroid Carcinoma: Toxicity and Survival Analysis

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 2, 2009, Pages 518-521

  Dandekar, Prasad ^a   Harmer, Clive ^a   Barbachano, Yolanda ^a   Rhys Evans, Peter ^a   Harrington, Kevin ^a   Nutting, Christopher ^a   Newbold, Kate ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Accelerated radiotherapy; Altered fractionation; Anaplastic thyroid cancer; Hyperfractionated radiotherapy; Radiation toxicity

Indexed keywords

ACCELERATED RADIOTHERAPY; ALTERED FRACTIONATION; ANAPLASTIC THYROID CANCER; HYPERFRACTIONATED RADIOTHERAPY; RADIATION TOXICITY;

BIOLOGICAL ORGANS; DISEASE CONTROL; RADIOTHERAPY;

TOXICITY;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DESQUAMATION; DOSIMETRY; DYSPHAGIA; ERYTHEMA; ESOPHAGITIS; FEMALE; HUMAN; HYPERFRACTIONATED ACCELERATED RADIOTHERAPY; MALE; MASTOID; MUCOSA INFLAMMATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT FAILURE; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA; CLINICAL PROTOCOLS; CONFIDENCE INTERVALS; DEGLUTITION DISORDERS; DOSE FRACTIONATION; ERYTHEMA; ESOPHAGITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIATION INJURIES; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 65449172765     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.08.016     Document Type: Article

References (22)

1. Tan R.K., Finley III R.K., Driscoll D., et al. Anaplastic carcinoma of the thyroid: A 24-year experience. Head Neck 17 (1995) 41-47 discussion, 47-48
2. Hadar T., Mor C., Shvero J., et al. Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 19 (1993) 511-516
3. Chang H.S., Nam K.H., Chung W.Y., et al. Anaplastic thyroid carcinoma: A therapeutic dilemma. Yonsei Med J 46 (2005) 759-764
4. Kebebew E., Greenspan F.S., Clark O.H., et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103 (2005) 1330-1335
5. Ahuja S., and Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10 (1987) 303-310
6. Mitchell G. Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 50 (1999) 33-38
7. Wang Y., Tsang R., Asa S., et al. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 107 (2006) 1786-1792
8. Hollinsky C., Kober F., Hermann M., et al. [Prognostic factors in highly malignant thyroid tumors]. Wien Klin Wochenschr 102 (1990) 249-253
9. Junor E.J., Paul J., and Reed N.S. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 18 (1992) 83-88
10. Haigh P.I., Ituarte P.H., Wu H.S., et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91 (2001) 2335-2342
11. Nilsson O.L.J., and Zedenius J. Anaplastic giant cell carcinoma of the thyroid gland: Treatment and survival over a 25 year period. World J Surg 22 (1998) 725-730
12. Passler C., Scheuba C., Prager G., et al. Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg 384 (1999) 284-293
13. Venkatesh Y.S.O.N., Schultz P.N., Hickey R.C., et al. Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 cases. Cancer 66 (1990) 321-330
14. DeMeter J.G.D.J.S., Lawrence A.M., and Paloyan E. Anaplastic thyroid carcinoma: Risk factors and outcome. Surgery 110 (1991) 956-963
15. Jereb B., Stjernsward J., and Lowhagen T. Anaplastic giant-cell carcinoma of the thyroid. A study of treatment and prognosis. Cancer 35 (1975) 1293-1295
16. Ishiwata I., Ono I., Kiguchi K., et al. Establishment and characterization of a human thyroid carcinoma cell line (HOTHC) producing colony stimulating factor. Hum Cell 18 (2005) 163-169
17. Oka Y., Kobayashi T., Fujita S., et al. Establishment of a human anaplastic thyroid cancer cell line secreting granulocyte colony-stimulating factor in response to cytokines. In Vitro Cell Dev Biol Anim 29A (1993) 537-542
18. Palyi I., Peter I., Daubner D., et al. Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101). Virchows Arch B Cell Pathol Incl Mol Pathol 63 (1993) 263-269
19. Tennvall J., Lundell G., Wahlberg P., et al. Anaplastic thyroid carcinoma: Three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86 (2002) 1848-1853
20. De Crevoisier R., Baudin E., Bachelot A., et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 60 (2004) 1137-1143
21. Milano A., Chiofalo M.G., Basile M., et al. New molecular targeted therapies in thyroid cancer. Anticancer Drugs 17 (2006) 869-879
22. Wiseman S.M., Masoudi H., Niblock P., et al. Anaplastic thyroid carcinoma: Expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 14 (2007) 719-729